资料图（图片来源： 视觉中国 ） 云南白药 牙膏止血到底靠什么，官方的回应中并未提及。 "6大白药活性因子，具有活血、抑菌、止血、修复、抗炎及骨细胞生长的独特作用，全面保健牙 周。"这是云南白药官网上对其一款牙膏的介绍。 牙膏是云南白药（000538.SZ）健康板块的主要产品。根据云南白药公告，"该产品市场占有率位居全国 第二位、民族品牌第一位"。而"止血"正是云南白药牙膏的重要卖点。 不过，近日一位血液科医生去超市买牙膏，发现云南白药牙膏中含有止血西药成分：氨甲环酸，这令她 心中不解："这种牙膏的止血作用成分，究竟是中草药还是止血处方药？"她将文章发到了网络上，引爆 了舆论。 氨甲环酸是什么？这种西药成分能否添加到牙膏中？云南白药牙膏中起到止血作用的到底是"白药活性 因子"还是氨甲环酸？ 中草药牙膏里起止血作用的是西药成分？ 10月21日，认证为三甲医院血液科执业医师的网友"科普医生博雅"发表文章称，她在云南白药中草药牙 膏成分中发现了氨甲环酸，并指出，这是血液科医生常用的止血药，并且还是处方药。该网友发现，很 多号称能防止牙龈出血的中草药牙膏均含有该成分，因此该网友怀疑这些号称能防止牙龈出血的中草药 牙膏 ...

中国是世界第一大牙膏生产国、消费国和出口国，去年市场整体销售额为339.8亿元，同比增长0.86%。 从销售渠道结构来看，仍然以线下为主，占比达75.96%。下面我们就根据尼尔森零售研究报告（按销 售额计），简单介绍一下行业竞争格局。 葛兰素史克（舒适达）、纳美分别排在第八、九位，市占率均不足3%。联合利华（中华）名列第七， 市占率4.06%。中华牙膏原属于上海牙膏厂，诞生于上世纪50年代中期，市场份额一度高达四成，94年 联合利华取得品牌经营权。虽然早已从销量第一的宝座滑落下来，但时至今日，中华仍然是集团口腔护 理业务支柱。 薇美姿（舒客）以4.88%的份额排在第六。2022年2月，薇美姿启动了赴港上市计划。该公司成立于06 年，旗下拥有牙膏、牙刷品牌舒客、舒客宝贝，通过"高端做形象、低端冲销量"的战略模式，签约贝克 汉姆、李冰冰等大牌明星担任品牌代言人，与舒克贝塔、迷你特工队等IP展开联名，快速打响知名度。 写在最后 虽然外资品牌仍旧强势，但本土品牌也不容小觑，通过产品结构的持续升级、渠道运作的持续精耕，竞 争实力已逐步赶超外资品牌，重新占据主导地位。值得注意的是，随着消费者需求的多元化，口腔护理 行业早 ...

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of CNY 4.751 billion, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year growth of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] Group 2: Online Sales and Marketing - The pharmaceutical business group expanded its online market, with O2O sales increasing by over 20% year-on-year [3] - During the 2025 "618" shopping festival, the company’s main products ranked significantly higher on the regular medicine list [3] - E-commerce platforms attracted 48.45 million visitors, resulting in 3.54 million consumers and generating a GMV of CNY 254 million [3] Group 3: Health Products Strategy - The health products group aims to become a leader in high-quality health lifestyle products, focusing on oral care and hair care [4] - Continuous enhancement of oral product advantages and rapid scaling of hair care business are key objectives for the second half of the year [4] Group 4: Nuclear Medicine Development - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [5] - The INR102 therapeutic nuclear medicine project has received clinical trial approval, with 12 patients enrolled in Phase I trials [5] Group 5: Traditional Chinese Medicine Resource Development - The Chinese medicine resource group focuses on Yunnan's local medicinal materials, achieving significant results through collaborative efforts [6] - The establishment of 14 seed source bases and the completion of 90% of the annual target for quality seed promotion [6] - The digital cloud medicine platform achieved a transaction volume exceeding CNY 1 billion, with 18,000 registered farmers [6] Group 6: Future Directions for Provincial Pharmaceutical Company - The provincial pharmaceutical company plans to enhance market share in existing hospitals and distribution channels while exploring new growth areas [8] - Strategies include optimizing supply chain management and improving accounts receivable and inventory structure [8]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of 4.751 billion yuan, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded 1.453 billion yuan, with a significant year-on-year growth of over 20.9% [2] - Other core products, including Yunnan Baiyao plaster and capsules, also saw notable growth, contributing to the overall revenue increase [2] - Plant-based products, such as Qixue Kang oral liquid, reached sales of 202 million yuan, with a year-on-year growth of approximately 116.2% [2] Group 2: Health Product Channel Development - The company has established a comprehensive national sales team for health products, maintaining a leading market share in Yunnan Baiyao toothpaste [4] - Continuous optimization of the entire channel has strengthened traditional offline advantages while also focusing on emerging retail formats like instant retail and community group buying [4] Group 3: Traditional Chinese Medicine Cultivation Achievements - The company has implemented a precise research and transformation model for seed innovation, achieving coverage of ten major Yunnan medicinal sources [5] - The area of high-quality seed promotion has reached 90% of the annual target, with significant progress in the construction of "Yun Medicine Seed Valley" [5] - Over 7,000 acres of GAP management have been added for various medicinal herbs, integrating low-altitude economy and IoT technology [5] Group 4: Online Sales Performance - The pharmaceutical business group has expanded its online market, with O2O sales increasing by over 20% year-on-year [6] - During the 2025 "618" shopping festival, the company achieved a GMV of 254 million yuan through e-commerce platforms, attracting 48.45 million visitors [7] - Yunnan Baiyao toothpaste maintained the top market share in the domestic channel, while Yangyuan Qing ranked first in Tmall for anti-hair loss shampoo [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [8] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled [8]

文 | 酒管财经 两面针又要扩产了，还是针对酒店牙膏和拖鞋项目。 作为原本的国民牙膏品牌，两面针在被"挤出"主流家用牙膏市场后，逐渐将旅游牙膏作为业务重点。只是，尽管保持着行业领先的市占率，但其盈利能力出 现明显的下滑。 要知道，在第三季度，两面针一支旅游牙膏只卖8分钱。并且，这样的售价几乎维持了近十年时间。 酒店牙膏，是解药也是毒药？ 在扬州杭集镇，两面针正在筹划建设中草药功能性口腔护理产品生产基地扩建项目。该公司计划投资6885.22 万元，建设一个牙膏生产车间和酒店用拖鞋生 产车间。 前者将整合现有牙膏生产线，满足公司酒店牙膏生产需要的同时，满足客户 OEM 等定制类产品要求。后者则将有效降低对外采购依赖，完善产品配套能 力，巩固并提升市场份额。 深耕酒店业务，似乎并没有让两面针发扬壮大。押宝酒店，但又困于酒店，这不是两面针一家企业面临的难题。几乎所有传统耗品企业品牌都有类似的遭 遇。 两面针的确需要扩大酒店牙膏产能，因为原本设计的产能几乎已经满产了。 究竟是酒店赛道天然存在利润不足，还是外界多重因素压榨了供应链企业的利润？这非常值得我们关注。 两面针最近一次披露产能利用率是在2024年财报中。 公司年 ...

1902年，22岁的年轻医生曲焕章遍游滇南，亲尝百草，反复试验，经十载钻研试验，研制出对治疗刀枪 伤和跌打损伤有奇效的"万应百宝丹"。 从制造到智造 一百多年来，云南白药从"万应百宝丹"脱胎，由一个传统中药品牌蜕变为横跨医药、健康、日化等多领 域的现代化医药产业集团。 作为云南省首家上市公司，云南白药登陆资本市场32年来，各项指标实现跨越式发展：营业收入从0.58 亿元增长到去年的400.33亿元，增长690倍；净利润从0.13亿元增长到去年47.49亿元，增长365倍…… 在云南白药党委书记、董事长张文学看来，这家"百年老店"是一个传统中药企业顺应时代及行业趋势， 准确把握自身禀赋，不断超越自我，持续焕发活力的企业样本。"保持战略定力，用战略的确定性、执 行的有效性，应对外部环境的不确定性，持续提升战略引领能力。心无旁骛做好产品才是成功的关 键。"他说。 在云南白药牙膏智慧工厂里，7500个传感器静静闪烁着，56个最小功能单元灵活切换，一支支牙膏在无 人流水线上鱼贯而出……这一生动的场景，成为中药企业拓展大健康领域的标杆。 今年9月，这座工厂获评"灯塔工厂"，成为全球中医药健康品领域首个获此认证的生产基地。 ...

Group 1 - Dongyangguang Pharmaceutical's total revenue from 2022 to 2024 is projected to reach 14.2 billion, with R&D investment of 2.5 billion over the past three years, and operating profit exceeding 2.1 billion in the last two years [21] - Huaren Sanjiu's R&D investment is expected to reach 950 million in 2024, a 63.97% increase from 2020, with R&D personnel increasing to 876, more than double that of 2020 [21] - Yunnan Baiyao achieved a net profit of 4.777 billion in the first three quarters of 2025, a year-on-year increase of 10.41%, surpassing the full-year profit of 4.749 billion in 2024, marking a historical high for the same period [21] Group 2 - Yunnan Baiyao emphasizes the importance of returning to its core business and focusing on continuous effective R&D investment to build a competitive moat [22] - Huaren Sanjiu is accelerating its merger and integration pace, focusing on consumer health, medical health, and elderly health sectors, while enhancing R&D investment to drive innovation transformation [22] - Dongyangguang Pharmaceutical has developed three self-researched new drugs and has nearly 50 new drugs in the pipeline, actively seeking international markets for growth [26][31] Group 3 - Yanhuilong has invested over 1 billion in R&D from 2021 to 2024, with annual R&D investment accounting for over 20% of its main business revenue [21][51] - The company is shifting from rapid market capture to deep innovation, focusing on high-quality development and establishing a unique project advantage in the IVD industry [49][50] - Yanhuilong's overseas revenue exceeded 200 million in the first three quarters, a nearly 40% year-on-year increase, indicating successful market expansion [54] Group 4 - Yunnan Baiyao's revenue has grown from 58 million to 40.033 billion over 32 years, a 690-fold increase, with net profit rising from 1.3 million to 4.749 billion, a 365-fold increase [40] - The company has established a digital transformation strategy, creating a full-chain digital system to enhance operational efficiency and product quality [41][42] - Yunnan Baiyao's strategic planning includes three R&D curves focusing on traditional Chinese medicine, innovative drugs, and nuclear medicine [48] Group 5 - Dongyangguang Pharmaceutical has built a comprehensive R&D system and a modern factory with an annual production capacity of 1.8 billion tablets [29] - The company is actively integrating AI into drug discovery processes to enhance efficiency and reduce costs [30] - Huaren Sanjiu's revenue is projected to reach 27.6 billion in 2024, a 102% increase from 2020, with a compound annual growth rate of 23.6% in revenue and 24.5% in profit over the past three years [35]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical segment achieved a revenue of CNY 4.751 billion, representing a year-on-year growth of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year increase of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] - Plant-based products, such as Qixue Kang Oral Liquid, reached sales of CNY 202 million, with a year-on-year growth of approximately 116.2% [2] Group 2: Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 22 activated, enrolling 60 subjects [3] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled for Phase II trials [3] Group 3: Health Products Business Performance - The health products segment reported a revenue of CNY 3.442 billion in the first half of 2025, reflecting a year-on-year growth of 9.46% [4] - The segment focuses on a full-channel operation strategy, enhancing offline distribution capabilities and increasing online channel investments [4] - The oral care category, particularly gum care toothpaste, maintains and gradually expands its leading advantage, while anti-sensitivity toothpaste shows breakthrough growth [4] Group 4: Online Sales Performance - The pharmaceutical segment's online sales increased by over 20% year-on-year, with a GMV of CNY 254 million generated from 4.845 million visitors [5] - Yunnan Baiyao toothpaste holds the top market share in the domestic all-channel market, while Yangyuanqing shampoo ranked first in Tmall's domestic anti-hair loss category during the 2025 "618" shopping festival [5] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of CNY 11.85 per 10 shares, totaling CNY 2.164 billion [6] - The total cash dividend for 2024, including special dividends, amounted to CNY 23.98 per 10 shares, representing 90.09% of the net profit attributable to shareholders [7] - In the first half of 2025, the company distributed a cash dividend of CNY 10.19 per 10 shares, totaling CNY 1.818 billion, with special dividends accounting for 50.05% of the net profit for the period [7]

Core Insights - The article highlights a shift in consumer behavior towards higher quality products and differentiated marketing strategies in the e-commerce industry, marking the era of value attraction [1] - Yunnan Baiyao has successfully adapted to this trend by focusing on product quality and emotional marketing, leading to significant sales growth during the Double Eleven shopping festival [4][8] Group 1: Sales Performance - Yunnan Baiyao's total e-commerce GMV exceeded 760 million, showing a year-on-year growth of over 40%, with multiple product lines experiencing substantial growth [4] - The company achieved remarkable sales milestones, with two stores surpassing 100 million in sales and ten stores exceeding 10 million [4] Group 2: Emotional Marketing - Yunnan Baiyao has optimized the entire consumer ordering process, enhancing product structure, emotional engagement, and trust reinforcement, which has led to increased brand recognition [9] - The brand effectively combines traditional Chinese medicine with modern entertainment, appealing to younger consumers through live streaming and short videos [10][16] Group 3: Product Innovation - The launch of the new Guangzhuan White Toothpaste has been a significant success, generating over 11 million in a single live stream and achieving overall sales exceeding 100 million [8] - Yunnan Baiyao has upgraded its product packaging and formulations to meet consumer demands for quality and usability, such as the innovative "small golden top" bottle cap design [23] Group 4: Market Positioning - The company is leveraging AI technology to enhance production efficiency and product quality, positioning itself as a leader in the traditional Chinese medicine and health product market [35][39] - Yunnan Baiyao's marketing strategies focus on creating relatable and engaging content that resonates with consumers, thereby strengthening brand loyalty and trust [34][39] Group 5: Consumer Engagement - The brand has successfully engaged with younger demographics through targeted marketing campaigns and events, achieving over 650 million online exposures and a significant presence among Generation Z [16] - By integrating educational content and interactive experiences, Yunnan Baiyao is enhancing consumer knowledge and satisfaction, leading to a more informed purchasing decision [18][33]

Core Viewpoint - The market value of Yunnan Baiyao is under pressure due to the overall downturn in the traditional Chinese medicine industry, despite its stable revenue and profit growth. The company is facing challenges in maintaining growth momentum and diversifying its product offerings [1][3][19]. Financial Performance - Yunnan Baiyao reported a revenue of 30.65 billion yuan for the first three quarters, a year-on-year increase of 2.47% [3][5]. - The net profit attributable to shareholders reached 4.78 billion yuan, reflecting a year-on-year growth of 10.41% [3][5]. - The company's basic earnings per share increased by 10.74% to 2.68 yuan [5]. Revenue Composition - The company's revenue is heavily reliant on commercial sales, which account for 60% of total revenue but have a low gross margin of only 6% [6]. - Industrial sales, which make up less than 40% of revenue, are the main profit contributors, particularly from products like aerosol sprays and toothpaste [6]. Market Position and Challenges - Yunnan Baiyao holds a dominant market share in several product categories, including a 91.8% share in the aerosol market for muscle and joint pain relief [6]. - Despite its strong market position, the company faces challenges in growth as sales in pharmaceuticals and health products have slowed down in recent years [7]. Diversification Efforts - In recent years, Yunnan Baiyao has explored various side businesses, including tea and industrial hemp, and previously engaged in stock trading, which led to significant losses [8][14]. - The company has since reduced its trading financial assets significantly, indicating a shift in strategy towards safer investments [10][11]. Strategic Developments - Yunnan Baiyao has announced plans to focus on both traditional Chinese medicine and innovative pharmaceuticals, aiming for both internal and external growth [26][27]. - The acquisition of 聚药堂 for 660 million yuan is part of its strategy to enhance its product portfolio and market reach, despite concerns over the high premium paid [28][30]. Innovation and R&D - The company is actively pursuing innovation in its product lines, with ongoing projects in traditional Chinese medicine and health supplements [32][36]. - Yunnan Baiyao is also working on developing new drugs, although the process is lengthy and costly, posing risks to timely market entry [36]. Market Outlook - Despite recent challenges, Yunnan Baiyao has maintained a high dividend payout ratio, making it attractive to investors [36]. - The company's current valuation is below the industry average, suggesting potential for future growth, although caution is advised before making investment decisions [36].